Dr. Pablo Lapuerta M.D., Chief Medical Officer

Former Global Executive Vice President / CMO of Lexicon Pharmaceuticals. Dr. Lapuerta got his M.D. Degree fromHarvard Medical School. He has more than 25 years of global clinical development experience, and extensiveexperience in forming and leading large teams. He has published more than 250 papers in various professional

magazines. He worked at Lexicon for about 10 years. Under his leadership, Sotaglifozin was approved byEMA for thetreatment of Type 1 Diabetes disease, and Xermelo was also approved by FDA He has also led many phase l andphase ll clinical studies.

Ms. Helen Wwang, Chairman of Youngene said:With Dr.Lapuerta's joining, Youngene will further strengthen the coreadvantages in clinical development, accelerate the boost of clinical projects and strengthen the company's overall eammanagement capabilities.

About Youngene Therapeutics:

Youngene Therapeutics is a clinical stage pharmaceutical company with a primary focus on metabolic and cardiovasculardisease.In addition to this Phase 2 study,YG1699 completed a Phase 1 study in the USA and is currently beingevaluated in a pharmacokinetic bridging study in healthy volunteers in China.